Dotenoroxetine: An "old drug" for Alzheimer's disease used for over 20 years, is it still worth knowing about? 🧠

While news of new Alzheimer's (AD) drugs frequently makes headlines, a drug called dotenorra may seem "out of fashion." However, in real clinical practice, this "old drug," which has been used for over two decades, remains an indispensable cornerstone of treatment for most Alzheimer's patients worldwide. It may not be perfect, but a deep understanding of it is crucial for patients' families. ✨

Not a "rising star," but a "foundation stone" 💎

Donepezil (generic name: Donepezil, brand name: Aricept®) belongs to the class of acetylcholinesterase inhibitors. The development of this class of drugs is based on a core discovery: in the brains of Alzheimer's disease (AD) patients, the levels of acetylcholine, a key chemical messenger responsible for memory and cognition, are significantly reduced.

You can think of it as a signal amplifier: when neurons in the brain that transmit memory signals gradually die and the signals weaken, dotenoroxetine temporarily improves cognitive function by inhibiting the "noise" (enzymes that break down acetylcholine) that destroys the signals, allowing the remaining signals to be received more clearly.

What can it do? Realistic expectation management📈

The primary goal of dotenoroxetine is to improve symptoms and slow clinical decline, rather than to cure the disease.

The benefits confirmed by research typically include:

• Cognitive stabilization period: After medication, approximately 50%-60% of patients experience a significant slowdown in the decline of their memory, attention, and language abilities within 6-12 months. In the long course of Alzheimer's disease, this is equivalent to gaining a valuable "plateau period."
• Maintenance of daily living abilities: May help patients maintain basic self-care abilities for a longer period of time, such as dressing, eating, and personal hygiene.
• Improvement of psychosocial symptoms: It has a mitigating effect on symptoms such as apathy, anxiety, and irritability in some patients.

Limitations that must be faced:

• The effect is temporary: the therapeutic effect usually gradually diminishes after the moderate to severe stage.
• Irreversible damage: It cannot repair dead brain cells, nor can it remove pathological proteins in the brain (such as beta-amyloid).
• Response varies from person to person: about 1/3 of patients have a significant response, 1/3 have a moderate response, and 1/3 may have little effect.

Side effects: The "costs" to be wary of ⚠️

Due to its pharmacological effects, the side effects are mainly related to the overactivation of the cholinergic system.

1. Gastrointestinal reactions (most common): nausea, vomiting, diarrhea, decreased appetite. These usually occur when starting the medication or increasing the dose and may lessen as the body adapts. 🤢
2. Nervous system effects: dizziness, insomnia, unusually vivid dreams, and muscle cramps in a few people.
3. Cardiac risks: May cause bradycardia; contraindicated in patients with pre-existing severe cardiac conduction problems. 🫀
4. Medication strategy: To reduce side effects, the standard usage is to start with a low dose (e.g., 5 mg/day), and after one month, assess tolerability before considering increasing to the standard dose (10 mg/day).

Its place in the new era of treatment 🗺️

With the approval of disease-modifying therapies targeting Aβ (such as lencanezumab), the role of dotenorazole has undergone a subtle evolution, but has not been replaced:

• The "ballast" of basic treatment: For the vast majority of AD patients worldwide, especially in regions where new therapies are unavailable or unaffordable, it remains the core first-line treatment option.
• A "partner" in combination therapy: In the future, "disease-modifying therapy + doxycycline valerate symptomatic treatment" is likely to become the standard treatment. The former aims to slow the fundamental progression of the disease, while the latter manages current symptoms simultaneously, working in tandem. 🤝
• Considerations throughout the course of the disease: When the disease transitions from moderate to severe, clinicians often consider combining it with another drug with a different mechanism of action—memantine (an NMDA receptor antagonist)—in order to obtain synergistic benefits.

Practical thoughts and suggestions for patients' families💡

1. When to start? Treatment can usually begin after a confirmed diagnosis of mild to moderate Alzheimer's disease (AD). Early and standardized medication may yield greater benefits.
2. When to adjust or discontinue medication? When the disease progresses to an advanced stage (e.g., MMSE score <10), the benefits of medication are no longer obvious, and the side effects (such as increased risk of aspiration due to difficulty swallowing) may outweigh the benefits. In such cases, medication should be discontinued under the guidance of a doctor.
3. What if it's "ineffective"? If a cholinesterase inhibitor is ineffective or the side effects are intolerable, switching to another drug in the same class (such as rivastigmine or galantamine) may still be effective.
4. More important than medication: Medication is only one part of comprehensive management. Non-pharmacological interventions—including regular physical activity, cognitive stimulation activities, social interaction, a balanced MIND diet, and caregiver support—are equally crucial for maintaining patients' quality of life and slowing functional decline. 🧩

Conclusion: Respect the value of "classics" 🌉

While medicine strives for "breakthroughs" and "miracles," we must respect "classic" drugs like dotenoroxetine. It represents one of our earliest and most successful biological interventions for Alzheimer's disease (AD), and despite its limited effectiveness, it has provided tangible help and hope to patients and their families over the past two decades.

This reminds us that in this long battle against Alzheimer's disease, improving the quality of life each day and delaying each loss of function is itself a victory. While hoping for the widespread availability of fundamental treatments, making scientific and rational use of the tools we have is the most responsible way to care for patients.

---

Disclaimer: This article is for informational purposes only and does not constitute any medical advice. The diagnosis and treatment of Alzheimer's disease are complex, and all medication decisions must be made under the comprehensive evaluation and guidance of a professional neurologist. 🩺